Dr. Sikorski is eFFECTOR’s chief medical officer as a retained consultant. He is managing director of Woodside Way Ventures, a consulting and investment firm that helps biotechnology companies and investors advance lifesaving technologies through clinical development. Prior, he served as the chief medical officer of FivePrime Therapeutics, a public biotechnology company, where he led the development of a biologics pipeline that spanned preclinical discovery through proof of concept to pivotal registration trials. Earlier in his career, Dr. Sikorski led an early stage clinical development group at Medimmune/AstraZeneca. Before joining Medimmune, he led late stage clinical development and post marketing efforts for several commercial drugs and drug candidates at Amgen. Dr. Sikorski completed his residency at Massachusetts General Hospital and an Oncology fellowship at The Johns Hopkins Oncology Center after receiving a combined M.D. and Ph.D. from The Johns Hopkins University School of Medicine. He is a former editor of the journal Science and the Journal of the American Medical Association.